- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02364674
Transplant Optimization Using Functional Imaging (TROFI)
March 28, 2017 updated by: FLUIDDA nv
The objective of this study is to detect Bronchiolitis Obliterans Syndrome (BOS) in an early stage using the outcome parameters generated by Functional Respiratory Imaging (FRI).
Robust and automated segmentation algorithms will be developed for these parameters, focusing on quantitative computed tomography (CT) image analyses to provide the physician a more sensitive diagnostics tool.
The evolution of BOS over time will be monitored using non-rigid image registration methods.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Pennsylvania
-
Gibson, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patient ≥ 18 years old
- Written informed consent obtained
- Patient who had undergone a lung transplant a year ago or more.
- Female patient of childbearing potential who confirm that a contraception method was used at least 14 days before visit 1 and will continue to use a contraception method during the study
- The patient must be able to perform the lung monitoring at home.
Exclusion Criteria:
- Pregnant or lactating female
- Known history of or active airways or anastomotic complications requiring intervention such as stenting or dilation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: HRCT scans
HRCT scan will be taken
|
a HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5. An Upper Airway (UA) scan will be taken on visit 1.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Airway Volume (iVaw)
Time Frame: 12 months
|
Exploratory imaging endpoints: HRCT-scan will be taken at visit 1 - visit 5.
|
12 months
|
|
Airway Resistance (iRaw)
Time Frame: 12 months
|
Exploratory imaging endpoints: HRCT-scan will be taken at visit 1 - visit 5.
|
12 months
|
|
Specific Airway Volume (siVaw)
Time Frame: 12 months
|
Exploratory imaging endpoints: HRCT-scan will be taken at visit 1 - visit 5.
|
12 months
|
|
Specific Airway Resistance (siRaw)
Time Frame: 12 months
|
Exploratory imaging endpoints: HRCT-scan will be taken at visit 1 - visit 5.
|
12 months
|
|
Lobe volumes (iVlobes)
Time Frame: 12 months
|
Exploratory imaging endpoints: HRCT-scan will be taken at visit 1 - visit 5.
|
12 months
|
|
Air trapping
Time Frame: 12 months
|
Exploratory imaging endpoints: HRCT-scan will be taken at visit 1 - visit 5.
|
12 months
|
|
Internal Lobar Airflow Distribution
Time Frame: 12 months
|
Exploratory imaging endpoints: HRCT-scan will be taken at visit 1 - visit 5.
|
12 months
|
|
Low Attenuation or Emphysema Score
Time Frame: 12 months
|
Exploratory imaging endpoints: HRCT-scan will be taken at visit 1 - visit 5.
|
12 months
|
|
Blood Vessel Density or Fibrosis Score
Time Frame: 12 months
|
Exploratory imaging endpoints: HRCT-scan will be taken at visit 1 - visit 5.
|
12 months
|
|
Airway Wall Thickness
Time Frame: 12 months
|
Exploratory imaging endpoints: HRCT-scan will be taken at visit 1 - visit 5.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: David Lederer, M.D., M.S., Columbia University
- Principal Investigator: James Lee, M.D., M.S., University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Actual)
January 9, 2017
Study Completion (Actual)
January 9, 2017
Study Registration Dates
First Submitted
February 5, 2015
First Submitted That Met QC Criteria
February 17, 2015
First Posted (Estimate)
February 18, 2015
Study Record Updates
Last Update Posted (Actual)
March 29, 2017
Last Update Submitted That Met QC Criteria
March 28, 2017
Last Verified
February 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLUI-2014-103_USA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiolitis Obliterans
-
University Hospital, Basel, SwitzerlandRecruitingBronchiolitis Obliterans Syndrome (BOS) | Bronchiolitis Obliterans (BO)Switzerland, Saudi Arabia
-
Regend TherapeuticsShanghai Children's HospitalRecruitingPediatric Bronchiolitis ObliteransChina
-
Fondazione IRCCS Policlinico San Matteo di PaviaCompletedBronchiolitis Obliterans Syndrome (BOS)Italy
-
Brian KellerTherakosNot yet recruitingLung Transplant Failure and Rejection | Extracorporeal Photopheresis | CLAD, Bronchiolitis ObliteransUnited States
-
Shanghai General Hospital, Shanghai Jiao Tong University...Recruiting
-
Dompé Farmaceutici S.p.ARecruitingAtopic KeratoconjunctivitisSpain, Italy, United States
-
Azusa Pacific UniversitySacred Heart UniversityCompletedChronic | Neck Pain MusculoskeletalUnited States
-
WeiShiRecruitingGraft vs Host Disease | Chronic Graft-Versus-Host DiseaseChina
-
Institute of Hematology & Blood Diseases Hospital...Not yet recruitingChronic Graft-Versus-Host Disease
-
Washington University School of MedicineThe Foundation for Barnes-Jewish Hospital; Centers for Medicare and Medicaid... and other collaboratorsActive, not recruitingBronchiolitis Obliterans Syndrome (BOS)United States
Clinical Trials on High Resolution Computed Tomography scan
-
FLUIDDA nvCompletedBronchiolitis Obliterans | Lung Transplant RejectionBelgium
-
Superior UniversityActive, not recruitingIdiopathic Pulmonary FibrosisPakistan
-
Azienda Unita Sanitaria Locale di PiacenzaUniversity of ParmaRecruitingIdiopathic Pulmonary Fibrosis (IPF) | Interstitial Lung Disease Due to Systemic Disease (Disorder) | Reumatoid Arthritis | Connective Tissue Disease (CTD)Czechia, Italy
-
Assiut UniversityUnknownIdiopathic Pulmonary Fibrosis
-
Beijing Friendship HospitalBeijing Tongren Hospital; Beijing Obstetrics and Gynecology HospitalRecruitingVertigo | Hearing Loss | TinnitusChina
-
FLUIDDA nvCompletedChanges in Upper Airway GeometryBelgium
-
Assiut UniversityUnknown
-
University of California, San FranciscoCompletedOsteoporosisUnited States
-
FLUIDDA nvTerminatedBronchiolitis Obliterans | Lung Transplant RejectionBelgium